Abstract
PurposeTo evaluate safety and effectiveness of microwave ablation (MWA) in the treatment of liver metastases (LMs) secondary to non–small cell lung cancer (NSCLC). Materials and MethodsThis retrospective study included patients with NSCLC who underwent MWA of LM from March 2015 to July 2022. Local tumor progression-free survival (LTPFS) and overall survival (OS) were estimated using competing risk analysis and the Kaplan-Meier method. Postprocedural adverse events were recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. ResultsTwenty-three patients with 32 LMs were treated in 27 MWA sessions. The mean dimension of the largest index tumor was 1.96 cm (SD ± 0.75). Technical success was 100%. Technical effectiveness was achieved in 26 (81.3%) of 32 tumors. The median length of follow-up was 37.7 months (interquartile range, 20.5–54.5 months). The median LTPFS was 16.3 months (95% confidence interval [CI], 7.87–44.10 months). The median OS was 31.7 months (95% CI, 11.1–65.8 months). Ablation margin was a significant factor for LTPFS, with tumors ablated without a measurable margin being more likely to progress than those with measurable margins (subdistribution hazard ratios [HRs], 0.008–0.024; P < .001). Older age (HR, 1.18; 95% CI, 1.09–1.28; P < .001) and presence of synchronous lung metastases (HR, 14.73; 95% CI, 1.86–116.95; P = .011) were significant predictors of OS. Serious adverse events (CTCAE Grade ≥3) within 30 days occurred in 2 (7.4%) of 27 sessions, including pulmonary embolus and severe abdominal pain. ConclusionsPercutaneous MWA is a safe treatment for NSCLC LM, with longer survival noted in younger patients and those without synchronous lung tumors.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call